Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y , peptide YY and pancreatic polypeptide .[ 1] These receptors are involved in the control of a diverse set of behavioral processes including appetite , circadian rhythm , and anxiety .[ 2] [ 3] [ 4] [ 5] [ 6] [ 7]
Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP .
There are five known mammalian neuropeptide Y receptors designated Y1 through Y5 .[ 8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[ 9] [ 10] [ 11]
Antagonists [ edit ]
References [ edit ]
^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors" . Pharmacol. Rev. 50 (1): 143–50. PMID 9549761 .
^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi :10.1016/j.npep.2004.05.002 . PMID 15337373 .
^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi :10.1007/s00726-006-0334-x . PMID 16738800 .
^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry" . Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi :10.2174/156802607782341037 . PMID 17979774 .
^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide" . Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi :10.2174/157488906778773689 . PMID 18221213 .
^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease" . Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi :10.2174/156802607782340966 . PMID 17979780 .
^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi :10.1016/j.nut.2008.06.025 . PMID 18725086 .
^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi :10.1016/j.npep.2004.06.002 . PMID 15337367 .
^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi :10.1210/er.2007-0003 . PMID 17785427 .
^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs" . Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi :10.2174/156802607782341028 . PMID 17979781 .
^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?" . Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi :10.2174/156802607782340957 . PMID 17979782 .
External links [ edit ]
CGRP
Cholecystokinin
CRH
Galanin
Ghrelin/GHS
MCH
Melanocortin
Neuropeptide S
Neuropeptide Y
Neurotensin
Opioid
Orexin
Oxytocin
Tachykinin
Antagonists: Aprepitant
Befetupitant
Burapitant
Casopitant
CI-1021
CP-96,345
CP-99,994
CP-122,721
Dapitant
Ezlopitant
Figopitant
FK-888
Fosaprepitant
GR-203,040
GW-597,599
HSP-117
L-733,060
L-741,671
L-743,310
L-758,298
Lanepitant
LY-306,740
Maropitant
Netupitant
NKP-608
Nolpitantium besilate
Orvepitant
Rolapitant
RP-67,580
SDZ NKT 343
Serlopitant
Telmapitant
Tradipitant
Vestipitant
Vofopitant
Vasopressin